TD Private Client Wealth LLC Increases Stock Holdings in Becton, Dickinson and Company (NYSE:BDX)

TD Private Client Wealth LLC raised its position in shares of Becton, Dickinson and Company (NYSE:BDX - Free Report) by 44.6% in the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund owned 5,210 shares of the medical instruments supplier's stock after buying an additional 1,607 shares during the quarter. TD Private Client Wealth LLC's holdings in Becton, Dickinson and Company were worth $1,193,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. Brighton Jones LLC lifted its position in shares of Becton, Dickinson and Company by 98.2% during the fourth quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier's stock valued at $401,000 after buying an additional 877 shares during the last quarter. Wealth Enhancement Advisory Services LLC lifted its position in shares of Becton, Dickinson and Company by 50.6% during the first quarter. Wealth Enhancement Advisory Services LLC now owns 82,110 shares of the medical instruments supplier's stock valued at $18,808,000 after buying an additional 27,581 shares during the last quarter. Foster Victor Wealth Advisors LLC purchased a new stake in shares of Becton, Dickinson and Company during the first quarter valued at about $6,406,000. GAMMA Investing LLC lifted its position in shares of Becton, Dickinson and Company by 29.9% during the first quarter. GAMMA Investing LLC now owns 3,250 shares of the medical instruments supplier's stock valued at $744,000 after buying an additional 748 shares during the last quarter. Finally, Ritholtz Wealth Management purchased a new stake in shares of Becton, Dickinson and Company during the first quarter valued at about $224,000. 86.97% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Becton, Dickinson and Company

In other news, EVP David Shan sold 1,166 shares of the stock in a transaction that occurred on Monday, June 2nd. The stock was sold at an average price of $171.19, for a total transaction of $199,607.54. Following the transaction, the executive vice president owned 4,575 shares in the company, valued at $783,194.25. This trade represents a 20.31% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 0.36% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

BDX has been the subject of several research analyst reports. Stifel Nicolaus decreased their price objective on shares of Becton, Dickinson and Company from $280.00 to $224.00 and set a "buy" rating for the company in a research report on Friday, May 2nd. Barclays decreased their price objective on shares of Becton, Dickinson and Company from $261.00 to $241.00 and set an "overweight" rating for the company in a research report on Tuesday, June 3rd. Wall Street Zen lowered shares of Becton, Dickinson and Company from a "buy" rating to a "hold" rating in a research report on Friday, May 2nd. Citigroup lowered shares of Becton, Dickinson and Company from a "strong-buy" rating to a "hold" rating and decreased their price objective for the company from $217.00 to $185.00 in a research report on Thursday, May 22nd. Finally, Piper Sandler lowered shares of Becton, Dickinson and Company from an "overweight" rating to a "neutral" rating and decreased their price objective for the company from $260.00 to $185.00 in a research report on Friday, May 2nd. Eight research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company's stock. According to data from MarketBeat.com, Becton, Dickinson and Company presently has an average rating of "Hold" and a consensus price target of $219.22.

Becton, Dickinson and Company Stock Performance

Shares of NYSE BDX traded down $1.63 during midday trading on Friday, reaching $175.87. 2,428,715 shares of the stock were exchanged, compared to its average volume of 2,574,098. The firm has a market cap of $50.41 billion, a price-to-earnings ratio of 33.56, a PEG ratio of 1.33 and a beta of 0.25. Becton, Dickinson and Company has a twelve month low of $163.33 and a twelve month high of $251.99. The firm has a 50-day simple moving average of $172.19 and a two-hundred day simple moving average of $206.41. The company has a quick ratio of 0.64, a current ratio of 1.13 and a debt-to-equity ratio of 0.70.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last issued its quarterly earnings data on Thursday, May 1st. The medical instruments supplier reported $3.35 EPS for the quarter, topping analysts' consensus estimates of $3.28 by $0.07. The business had revenue of $5.27 billion for the quarter, compared to analysts' expectations of $5.35 billion. Becton, Dickinson and Company had a net margin of 7.28% and a return on equity of 15.99%. The business's revenue was up 4.5% on a year-over-year basis. During the same quarter last year, the company earned $3.17 EPS. As a group, analysts anticipate that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Monday, June 30th. Stockholders of record on Monday, June 9th were paid a dividend of $1.04 per share. The ex-dividend date was Monday, June 9th. This represents a $4.16 dividend on an annualized basis and a dividend yield of 2.37%. Becton, Dickinson and Company's payout ratio is 79.39%.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.